SAN DIEGO, Sept 17 (Bernama-GLOBE NEWSWIRE) — Sun Genomics, the direct-to-consumer custom probiotics and gut health company, announced today the close of $9.25 million in Series A funding. The round was led by Pangaea Ventures with new investments from Orion Fund, managed by K3 Ventures, and Emerging Technologies Partners. Additional investors include Danone Manifesto Ventures, SOSV, Human Longevity, and Nascita Ventures.
“Among the scientific and general community, the awareness and understanding of the gut microflora’s important impact on a person’s overall health and well-being is growing rapidly,” said MX Kuok, managing partner of K3 Ventures. “We are proud to support Sun Genomics’ scientifically rigorous approach to microbiome sequencing and customized probiotics, which has already improved lives in a quantifiable, measurable way.”